

Manuscript Evaluation Form

PAPER TITLE	Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients
AUTHOR(S) NAME	Yeting Chang, Yanchun Ding

Sec. A: REFEREE'S ASSESSMENT (cross as appropriate)

Criterion	Excellent	Good	Fair	Poor
Originality of the Topic	x			
Technical Quality	x			
Importance in its Field	x			
Style & Overall Representation		x		
Readily Understandable	x			
Suitability for the Journal	x			
Adequate Illustrations or Drawings	x			
English Language		x		

Description	Yes	No	Comments/Suggestions
Does the title represent manuscript's contents?	x		
Is the Abstract accurate and concise?	x		
Are the approaches/methods properly described?	x		
Are the conclusions and interpretations sound?	x		
Are the references properly cited?	x		
Is this a new/original contribution?	x		
Is it within the scope of the journal?	x		
Is the sample size adequate for the study?	x		

Overall the Paper is Rated:	(Excellent --8----- Poor)									
	10	9	8	7	6	5	4	3	2	1

Sec. B: REFEREE'S RECOMMENDATIONS**OTHER SPECIFIC CRITICISMS**

Accept with minor changes	<input checked="" type="checkbox"/>	Imperfect style	<input type="checkbox"/>
Accept with major changes	<input type="checkbox"/>	Too long	<input type="checkbox"/>
Reject in current form, but may be resubmitted	<input type="checkbox"/>	References incorrectly presented	<input type="checkbox"/>
Reject, with no resubmission	<input type="checkbox"/>	Typographical and Grammatical errors	<input checked="" type="checkbox"/>

PAPER TYPE: Research article	<input checked="" type="checkbox"/>	Review article	<input type="checkbox"/>	Letter article	<input type="checkbox"/>
Systematic review article	<input type="checkbox"/>	Case Report	<input type="checkbox"/>	Clinical Trial Study	<input type="checkbox"/>
Other	<input type="text"/>				

Have the following Reporting Guidelines been used by the authors in this study (if applicable)?

- **Randomized Controlled Trials** – CONSORT – Consolidated Standards of Reporting Trials
- **Observational Studies** – STROBE – Strengthening the Reporting of Observational studies in Epidemiology
- **Systematic Review of Controlled Trials** – PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- **Study of Diagnostic accuracy/assessment scale** – STARD – Standards for the Reporting of Diagnostic Accuracy Studies
- **Case Reports** – CARE – for case reports

Yes	No
Yes	No
Yes	No
Yes	No
Yes	No

Does the manuscript comply for Ethical Guidelines (if applicable)?

- Has the author provided the approval from local institutional review board? Or does the manuscript conform to the Helsinki Declaration on human experiments in the “Methods” section?
- Has the approval of institutional ethics committee been obtained by the author regarding experimentation on animals or other species? Is the name of the species mentioned in the title abstract and “Methods” Section of the article?
- In case of experimentation on human subjects, has informed consent been taken?

Yes	No
-----	----

Yes	No
-----	----

Yes	No
-----	----

Confidential Comments to the Editor (not for Transmission to Authors):**Comments for the Authors (continue on another sheet, if necessary):**

Review of the article entitled „Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients“, by Yeting Chang, Yanchun Ding

This article is a significant contribution, within the scope of the journal and suitable for publication after some revision.

The English language should be improved at some places.

On page 1, in the title of the article, state on moderate primary hypertension outpatients

On page 2, in the abstract, methods, line 3, state combined therapy (CT)

The objective of the abstract should be

To investigate the clinical effect of Perindopril or irbesartan combined with diltiazem on moderate primary hypertension outpatients.

Within the results of the abstract, in the second sentence, it can be added that

SBP, DBP, IVST, LVPWT, and LVMI were decreased significantly after the treatment with CT and RASI ($p < 0.05$). This should be mentioned in the final conclusion also.

Some statements from the conclusions in the abstract can also be mentioned in the final conclusion of the article.

The results obtained in this study show that RASI combined with diltiazem can attenuate left ventricular hypertrophy as compared with diltiazem or RASI alone.

In Keywords, Combined therapy can be stated after Perindopril, Diltiazem

On page 3, paragraph 2, line 4, replace has been instead of have been

On page 4, paragraph 1, line 1, use the first small letters for C-reactive protein

Paragraph 3, line 2, use the first capital letter for Hospital of Dalian Medical University

Line 4, add (1) before three blood pressure measurements (BPM)

Line 8, use superscript for square meters, 125 g/m^2 and 110 g/m^2

Use one space between the number and the unite of measure in the entire manuscript

On page 5, paragraph 2, lines 5 and 6, use the past tense in the sentence

After two weeks, if the blood pressure was higher than 160/100 mmHg, the subjects would be given more antihypertensive drugs

On page 6, move subtitle DCG to the next page

On page 8, in the footnote of Table 1, state at one place, after *AST* Aspartate Transaminase, *LDH* low-density lipoprotein

Delete *LDL-c* High-density lipoproteins cholesterol, after *TBil* Total bilirubin

Provide in Table 1 the data for eGFR estimated glomerular filtration rate, mentioned in the footnote of this table.

On page 9, paragraph 1, line 3, it can be stated that the diastolic pressure between the three groups has shown no significant statistical difference

On page 12, paragraph 1, line 6, delete one repeated the before blood supply

Paragraph 2, line 8, add comma before, such as

On page 14, paragraph 2, the second sentence of conclusion can be improved, for example as follows

Although ACE has no direct effect on coronary artery dilatation, the inotropic and chronotropic effects, it is proved, in the studies of Tang Linqing and Wang Xining et al., to have anti-myocardial ischemia effect.

Provide the issue numbers in references 1, 2, 7 and 13.

Format the entire manuscript according to the style of the journal.

FIELD OF EXPERTISE OF REFEREE: Materials, chemistry, medicinal and pharmaceutical chemistry, chemical technologies, nanotechnologies, biomedical engineering, spectroscopy

Name & Affiliation of Referee: Tamara Jovanovic, Department of Biomedical Engineering, Faculty of Mechanical Engineering, University of Belgrade, Kraljice Marije 16, 11120 Belgrade, Serbia

Tamara Jovanovic, December 25, 2021

SIGNATURE OF REFEREE / DATE